109166 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal Peptide nucleic acid, PNA
SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR IDIOPATHIC PULMONARY FIBROSIS
#2SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY
#3Compounds and Methods for Reducing ATXN3 Expression
#4TEMPORAL CONTROL OF CRISPR-Cas9 ACTIVITY USING BIOORTHOGONAL CHEMISTRY
#5Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#6GENETIC SEQUENCE-CARBOHYDRATE CONJUGATES FOR ENHANCED LIVER- AND KIDNEY-SPECIFIC TARGETING
#7ANTISENSE OLIGONUCLEOTIDE COMPLEX
#8METHODS OF TREATING OSMIDROSIS
#9ACTIVE TARGETING MICRORNA OLIGONUCLEOTIDE THERAPEUTICS FOR THE TREATMENT OF CARDIO-METABOLIC DISEASES
#10miR-141-3p MODULATORS AND USES THEREOF
#11PEPTIDE NUCLEIC ACID CONJUGATES
#12Methods for Treating Glioblastoma by Targeting Oncomirs
#13ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN
#14METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#15COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION
#16COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#17COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#18COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#19PEPTIDE NUCLEIC ACIDS FOR SPATIOTEMPORAL CONTROL OF CRISPR-CAS BINDING
#20GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT
#21METHODS OF TREATING OSMIDROSIS
#22CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#23Oligonucleotide Comprising Inosine for Treating DMD
#24COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#25CRISPNA FOR GENOME EDITING
#26Target Ligand
#27On-Chip Nanoscale Storage System Using Chimeric DNA
#28RECONFIGURABLE DNA NANO-TWEEZER
#29EXOSOMAL LOADING USING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES
#30COMPOUNDS AND METHODS FOR MODULATING PMP22
#31ANTI-SEED PNAS AND MICRORNA INHIBITION
#32MIR-96-5P INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
#33COMPOSITION COMPRISING OSTEOPONTIN INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF NEURODEGENERATIVE DISEASE
#34SIRNA OF ANGPTL3 AND USE THEREOF
#35Composition for regulating expression of PROX1 or expression of telomerase reverse transcriptase comprising activity regulator or method for screening telomerase reverse transcriptase regulator
#36COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#37NUCLEIC ACID MOLECULE HAVING IMPROVED STABILITY, AND USE THEREOF
#38PEPTIDE NUCLEIC ACID COMPLEX HAVING ENDOSOMAL ESCAPE CAPACITY, AND USE THEREOF
#39Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#40MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS
#41ENGINEERED NUCLEIC ACIDS AND USES THEREOF
#42Peptide nucleic acid conjugates
#43COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#44MIRNA-485 INHIBITOR FOR GENE UPREGULATION
#45EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#46Compositions and methods for delivery of nucleic acids to cells
#47Compositions and methods for delivery of nucleic acids to cells
#48ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
#49Compositions and methods for delivery of nucleic acids to cells
#50Dynamic pharmacokinetic-modifying anchors
#51HYDROXYMETHYL-MODIFIED GAMMA-PNA COMPOSITIONS AND METHODS OF USE THEREOF
#52MELANOPHILIN ANTISENSE OLIGONUCLEOTIDES
#53Modified peptide nucleic acid compositions
#54COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE
#55EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#56PEPTIDE NUCLEIC ACID COMPOSITIONS WITH MODIFIED HOOGSTEEN BINDING SEGMENTS AND METHODS OF USE THEREOF
#57COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#58SELECTIVE AMPLIFICATION USING BLOCKING OLIGONUCLEOTIDES
#59TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#60ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
#61NOVEL NUCLEIC ACID MODIFIERS
#62NOVEL NUCLEIC ACID MODIFIERS
#63ANTISENSE OLIGONUCLEOTIDE-BASED PROGRANULIN AUGMENTATION THERAPY IN NEURODEGENERATIVE DISEASES
#64COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#65Polycomb-associated Non-Coding RNAs
#66COMPOUNDS AND METHODS FOR REDUCING PMP22 EXPRESSION
#67ANTIBACTERIAL ANTISENSE AGENTS
#68Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
#69The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
#70CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#71AN RNA G-QUADRUPLEX STRUCTURE IN PRE-miRNA-1229 AS A THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE AND VARIOUS CANCERS
#72MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS
#73METHODS OF TREATING OSMIDROSIS
#74HIF 1-alpha antisense oligonucleotides
#75MATRIX METALLOPROTEINASE-1 ANTISENSE OLIGONUCLEOTIDES
#76Oligonucleotide comprising an inosine for treating DMD
#77Compounds and methods for increasing STMN2 expression
#78Composition for inhibiting CTGF expression
#79Antisense-induced exon exclusion in type VII collagen
#80METHODS FOR TREATING SICKLE CELL DISEASE
#81On-chip nanoscale storage system using chimeric DNA
#82HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
#83ANTISENSE ANTIBIOTICS AND BACTERIAL SECRETION BASED DELIVERY SYSTEM TO ELIMINATE DRUG-RESISTANT BACTERIA
#84Antisense molecules and methods for treating pathologies
#85Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping
#86Genome editing using effector oligonucleotides for therapeutic treatment
#87Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#88Methods and compositions for treating cancer using peptide nucleic acid-based agents
#89Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#90EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#91Peptide nucleic acid conjugates
#92Bivalent Nucleic Acid Ligands and Uses Therefor
#93COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS
#94TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#95Oligonucleotide comprising an inosine for treating DMD
#96Exosomal loading using hydrophobically modified oligonucleotides
#97Dynamic pharmacokinetic-modifying anchors
#98Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
#99Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#100Allele-specific therapy for Huntington disease haplotypes
#101Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)
#102Reconfigurable DNA nano-tweezer
#103Methods and compositions for managing vascular conditions
#104Engineered target specific base editors
#105Artificial single guide RNA and use thereof
#106SCN9A antisense pain killer
#107SNAP25 antisense oligonucleotides
#108EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES
#109Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#110POLYMER-BASED NANOPARTICLES, RELATED FORMULATIONS METHODS, AND APPARATUS
#111Methods and compositions for treating cancer using peptide nucleic acid-based agents
#112Chimeric double-stranded nucleic acid
#113Antisense molecules and methods for treating pathologies
#114Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#115Compounds and methods for reducing ATXN3 expression
#116MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#117PNA probe
#118MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#119Antisense-induced exon exclusion in type VII collagen
#120Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#121Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53
#122Targeting of human glucocorticoid receptor beta in cancer
#123Methods and compositions to increase the rate of ligation reactions catalyzed by a sortase
#124Nucleic acid nanoparticles for analyte detection
#125Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#126TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#127Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
#128Methods and compositions for managing vascular conditions
#129ANTISENSE MOLECULES FOR TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTION
#130Natural type miRNA for controlling gene expression, and use of same
#131Chimeric double-stranded nucleic acid
#132Oligonucleotides for modulating gene expression and uses thereof
#133MODIFIED 3' REGION EXTRACTION AND DEEP SEQUENCING OF POLYDENYLATION SITES AND POLY(A) TAIL LENGTH ANALYSIS
#134ANTISENSE COMPOSITIONS TARGETING ERWINIA SPECIES AND METHODS OF USING THE SAME
#135Selective amplification using blocking oligonucleotides
#136Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#137Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#138Nucleic acid functionalized nanoparticles for therapeutic applications
#139Antisense molecules and methods for treating pathologies
#140BIOPROBES AND METHODS OF USE THEREOF
#141MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#142Inhibition of lncRNA HOTAIR and related materials and methods
#143Modulation of nuclear-retained RNA
#144BIVALENT ANTISENSE OLIGONUCLEOTIDES
#145Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#146Chimeric double-stranded nucleic acid
#147Compositions and methods for modulating Tau expression
#148Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
#149Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#150EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#151Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#152Decoy oligonucleotides for the treatment of diseases
#153Compositions for enhancing targeted gene editing and methods of use thereof
#154Methods of Inducing Exon Skipping
#155METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
#156Methods of Inducing Exon Skipping
#157Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#158Allele-specific therapy for huntington disease haplotypes
#159BIOLOGICALLY ACTIVE NUCLEOTIDE MOLECULES FOR SELECTIVELY KILLING OFF CELLS, USE THEREOF, AND APPLICATION KIT
#160TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#161Peptide nucleic acid of porcine reproductive and respiratory syndrome virus and uses thereof
#162Oligonucleotide comprising an inosine for treating DMD
#163Exosomal loading using hydrophobically modified oligonucleotides
#164Exon skipping technology in VCP disease
#165PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS
#166Trans-acting elements for intracellular delivery of nucleic acid sequences
#167METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#168Diagnosis and treatment of Friedreich's ataxia
#169METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR
#170Polycomb-associated non-coding RNAs
#171METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#172Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#173Polycomb-associated non-coding RNAs
#174Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
#175cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY
#176Polycomb-associated non-coding RNAS
#177COMPOSITIONS AND METHODS OF USING MICRORNA INHIBITORS
#178Polycomb-associated non-coding RNAs
#179Polycomb-associated non-coding RNAs
#180Methods and compositions for treating cancer using peptide nucleic acid-based agents
#181MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS
#182Bioprobes and methods of use thereof
#183METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
#184Modular RNA regulators and methods
#185Antisense-induced exon2 inclusion in acid alpha-glucosidase
#186NEW CELL-SPECIFICALLY ACTIVE NUCLEOTIDE MOLECULES AND APPLICATION KIT FOR THE APPLICATION THEREOF
#187Antisense molecules for treatment of infection
#188Antisense molecules for treatment of infection
#189Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
#190Modulation of dystrophia myotonica-protein kinase (DMPK) expression
#191Genome editing using effector oligonucleotides for therapeutic treatment
#192Oligonucleotides for modulating gene expression and uses thereof
#193Compositions and methods for modulating Tau expression
#194Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#195METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS
#196EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#197ANTIGENE OLIGOMERS INHIBIT TRANSCRIPTION
#198Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#199Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#200EMBEDDED CHIMERIC PEPTIDE NUCLEIC ACIDS AND USES THEREOF
#201Modified cytosine polynucleotide oligomers and methods
#202Methods for modulating C9ORF72 expression
#203Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#204Nucleic acid functionalized nonoparticles for therapeutic applications
#205Piggy back delivery of nucleic acids into organisms
#206Methods and compositions for the specific inhibition of MYC by double-stranded RNA
#207Pharmaceutical composition comprising MicroRNA-30B, MicroRNA-133A, or MicroRNA-202-5P inhibitor for inhibiting cancer
#208Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)
#209Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#210Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#211Selective inhibition of polyglutamine protein expression
#212Gamma-PNA miniprobes for fluorescent labeling
#213Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
#214Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
#215Single-stranded nucleic acid aptamers specifically binding to and method for detecting using the same
#216PREPARATION OF PNA-6-AMINOGLUCOSAMINE CONJUGATES AS ANTIVIRAL AGENTS
#217Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#218Single-stranded nucleic acid molecule having amino acid backbone
#219Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#220Anti-influenza nucleic acid, peptide nucleic acid and preparations thereof
#221Antisense antiviral compound and method for treating influenza viral infection
#222Chimeric double-stranded nucleic acid
#223MicroRNA inhibitors
#224Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#225Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
#226Diagnosis and treatment of friedreich's ataxia
#227Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#228Methods and compositions for the specific inhibition of MYC by double-stranded RNA
#229Bioprobes and methods of use thereof
#230Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#231Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
#232Embedded chimeric peptide nucleic acids and uses thereof
#233Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#234Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#235Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#236TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY
#237TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
#238Method of inhibiting miR-33 using a modified oligonucleotide
#239Modulation of eIF4E expression
#240Antisense molecules and methods for treating pathologies
#241ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA
#242SPARC ANTISENSE COMPOSITIONS AND USES THEREOF
#243Method for modulating responsiveness to steroids
#244TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE
#245Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#246Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
#247Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
#248Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#249Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#250Cationic poly (amino acids) and uses thereof
#251OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#252Method for inhibiting the activity of mir-155
#253Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#254TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#255Modulation of exon recognition in pre-mRNA by interfering RNA structure
#256Antisense EGFRAS guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
#257Means and methods for counteracting muscle disorders
#258COMPOSITIONS AND METHODS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS
#259METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#260COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS
#261Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#262Selective inhibition of polyglutamine protein expression
#263Method for Introducing a Pna Molecule Conjugated to a Positively Charged Peptide into the Cytosol and/or the Nucleus by Photochemical Internalisation (Pci)
#264Chimeric Molecules to Modulate Gene Expression
#265ANTISENSE COMPOUNDS AND METHODS FOR DIAGNOSTIC IMAGING
#266Antisense antiviral compound and method for treating influenza viral infection
#267Use of antisense oligonucleotides to effect translation modulation
#268SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF
#269Method for inhibiting the activity of mir-155
#270Oligomeric compounds and compositions for use in modulation of pri-miRNAs
#271MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same
#272COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS
#273OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
#274MODULATION OF eIF4E EXPRESSION
#275Photocleavable sense-antisense complex
#276HYBRIDIZATION-STABILIZING CONSTRUCT
#277Biologically active molecules, particularly based on PNA and siRNA, method for the cell-specific activation thereof, and application kit to be administered
#278Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#279Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#280Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#281Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#282Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
#283HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF
#284Multifunction nanoconjugates for imaging applications and targeted treatment
#285Compounds for Hydrolyzing Ribonucleic Acids (RNA's)
#286ALLELE SUPPRESSION
#287Nucleic acid functionalized nanoparticles for therapeutic applications
#288SUPPRESSION OF POLYMORPHIC ALLELES
#289Modulation of eIF4E expression
#290Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#291Method for modulating responsiveness to steroids
#292Therapeutic Agents for the Treatment of Hmgb1-Related Pathologies
#293Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
#294Nucleic Acid Complex
#295Compounds and Their Use for Specific and Simultaneous Inhibition of Genes Involved In Diseases and Related Drugs
#296Peptide Nucleic Acid Conjugates and Uses Thereof
#297Dual-labeled molecular constructs for detection of biochemical reactions
#298G-rich polynucleotides as a novel therapeutic for the treatment of huntington's disease
#299Peptide-Pna Chimera Targeting Inducible Nitric Oxide Synthetase
#300Antisense modulation of CD40 expression